Show simple item record

dc.contributor.authorBeattie, Stuart G.
dc.contributor.authorGoetzman, Eric
dc.contributor.authorTang, Qiushi
dc.contributor.authorConlon, Thomas
dc.contributor.authorCampbell-Thompson, Martha
dc.contributor.authorMatern, Dietrich
dc.contributor.authorVockley, Jerry
dc.contributor.authorFlotte, Terence R.
dc.date2022-08-11T08:10:14.000
dc.date.accessioned2022-08-23T17:00:30Z
dc.date.available2022-08-23T17:00:30Z
dc.date.issued2008-10-23
dc.date.submitted2012-01-11
dc.identifier.citationJ Gene Med. 2008 Oct;10(10):1113-23. <a href="http://dx.doi.org/10.1002/jgm.1242">Link to article on publisher's site</a>
dc.identifier.issn1099-498X (Linking)
dc.identifier.doi10.1002/jgm.1242
dc.identifier.pmid18720429
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43808
dc.description.abstractBACKGROUND: Very long chain acyl coenzyme A (CoA) dehydrogenase (VLCAD) deficiency is a relatively common mitochondrial beta-oxidation disorder. The most severe form of VLCAD deficiency presents with neonatal cardiomyopathy and hepatic failure and is generally fatal within the first year of life. Mice deficient for long chain acyl CoA dehydrogenase (LCAD) closely resemble the clinical syndrome observed in VLCAD-deficient humans. Recombinant adeno-associated viral (rAAV) vectors with pseudotype capsids were investigated for their potential towards correcting the phenotype observed in mice heterozygous (+/-) for LCAD (i.e. liver and muscle steatosis). METHODS: rAAV containing the mouse LCAD cDNA (mLCAD) under the transcriptional control of the CMV/chicken beta-actin hybrid promoter were injected intramuscularly into the tibialis anterior (TA) muscle of LCAD(+/-) mice or injected into the portal vein to transduce hepatocytes. RESULTS: Ten weeks post-injection of rAAV1-mLCAD into the TA muscle, significantly increased levels of mLCAD within mitochondria were demonstrated by immunostaining of TA sections, immunoblotting of mitochondrial isolates and by the electron transfer flavoprotein (ETF) fluorescence reduction enzyme activity assay. Magnetic resonance spectroscopy of vector-injected TA muscle demonstrated a reduction in the lipid content compared to phosphate-buffered saline-injected mice, whereas a systemic effect was observed as a reduction in liver macrosteatosis. Eight weeks after portal vein injection of rAAV8-mLCAD into LCAD(+/-) mice, increased levels of mLCAD within hepatocyte mitochondria were demonstrated by immunostaining and also by the ETF assay. Scoring of the hepatosteatosis observed in partially deficient LCAD mice indicated a reduction in the lipid content within livers of vector-treated mice. CONCLUSIONS: These studies show that rAAV-mediated delivery of mLCAD was efficient and led to an amelioration of local and systemic pathologies observed in partially deficient LCAD mice.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18720429&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/jgm.1242
dc.subjectAcyl-CoA Dehydrogenase, Long-Chain
dc.subjectAnimals
dc.subjectDependovirus
dc.subjectFemale
dc.subjectGene Transfer Techniques
dc.subject*Genetic Vectors
dc.subjectLiver
dc.subjectMale
dc.subjectMice
dc.subjectTransduction, Genetic
dc.subjectAllergy and Immunology
dc.subjectGenetics and Genomics
dc.subjectPediatrics
dc.titleRecombinant adeno-associated virus-mediated gene delivery of long chain acyl coenzyme A dehydrogenase (LCAD) into LCAD-deficient mice
dc.typeJournal Article
dc.source.journaltitleThe journal of gene medicine
dc.source.volume10
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pulmonary/23
dc.identifier.contextkey2441384
html.description.abstract<p>BACKGROUND: Very long chain acyl coenzyme A (CoA) dehydrogenase (VLCAD) deficiency is a relatively common mitochondrial beta-oxidation disorder. The most severe form of VLCAD deficiency presents with neonatal cardiomyopathy and hepatic failure and is generally fatal within the first year of life. Mice deficient for long chain acyl CoA dehydrogenase (LCAD) closely resemble the clinical syndrome observed in VLCAD-deficient humans. Recombinant adeno-associated viral (rAAV) vectors with pseudotype capsids were investigated for their potential towards correcting the phenotype observed in mice heterozygous (+/-) for LCAD (i.e. liver and muscle steatosis).</p> <p>METHODS: rAAV containing the mouse LCAD cDNA (mLCAD) under the transcriptional control of the CMV/chicken beta-actin hybrid promoter were injected intramuscularly into the tibialis anterior (TA) muscle of LCAD(+/-) mice or injected into the portal vein to transduce hepatocytes.</p> <p>RESULTS: Ten weeks post-injection of rAAV1-mLCAD into the TA muscle, significantly increased levels of mLCAD within mitochondria were demonstrated by immunostaining of TA sections, immunoblotting of mitochondrial isolates and by the electron transfer flavoprotein (ETF) fluorescence reduction enzyme activity assay. Magnetic resonance spectroscopy of vector-injected TA muscle demonstrated a reduction in the lipid content compared to phosphate-buffered saline-injected mice, whereas a systemic effect was observed as a reduction in liver macrosteatosis. Eight weeks after portal vein injection of rAAV8-mLCAD into LCAD(+/-) mice, increased levels of mLCAD within hepatocyte mitochondria were demonstrated by immunostaining and also by the ETF assay. Scoring of the hepatosteatosis observed in partially deficient LCAD mice indicated a reduction in the lipid content within livers of vector-treated mice.</p> <p>CONCLUSIONS: These studies show that rAAV-mediated delivery of mLCAD was efficient and led to an amelioration of local and systemic pathologies observed in partially deficient LCAD mice.</p>
dc.identifier.submissionpathpeds_pulmonary/23
dc.contributor.departmentDepartment of Pediatrics
dc.contributor.departmentGene Therapy Center
dc.source.pages1113-23


This item appears in the following Collection(s)

Show simple item record